医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ResolutionMD® Receives Certification for Web and Mobile Diagnosis in Australia

2014年11月26日 PM10:35
このエントリーをはてなブックマークに追加


 

CALGARY

Calgary Scientific Inc., a company known for creating transformative technology for the medical industry and beyond, announced today that ResolutionMD® has received certification from the Australian Therapeutic Goods Administration (TGA) for diagnosis on both web and mobile devices for all imaging modalities. This certification enables medical practitioners to take advantage of the benefits of mobile diagnosis to improve patient care as they can now access a range of image storage systems and diagnostic tool sets from any location.

“Our customers have been talking about moving to mobile viewing for some time, the release of ResolutionMD® for the Australian market should be the opportunity for hospitals to move into an effective mobile solution that will substantially improve patient care,” says Scott Wilson, Siemens Business Manager for Syngo in Australia.

Obtaining the certificate from the TGA means healthcare organizations in Australia can feel confident using ResolutionMD®, the world’s leading enterprise image-viewing solution, to perform a clinical diagnosis using web, iOS or Android devices. The TGA certificate follows ResolutionMD’s FDA Class II clearance, CFDA certification, CE marking and Health Canada license.

“Obtaining this TGA certificate is another significant milestone for Calgary Scientific as we continue to expand globally,” said Pierre Lemire, President and CTO of Calgary Scientific. “I am pleased that our partners who operate in Australia can now offer ResolutionMD; enabling practitioners to make faster, more informed treatment decisions in their pursuit to deliver a new standard of patient care.”

About ResolutionMD®

ResolutionMD enables doctors to securely view patient images and reports from a wide variety of computers and mobile devices, collaborate with other practitioners and diagnose from any location. Whether you are a single facility or a large healthcare system with tens of thousands of users, ResolutionMD is the best choice for seamless image access across multiple departments. The CFDA registered, FDA cleared, Health Canada licensed, CE marked and TGA certified mobile medical diagnosis software can be integrated into any EMR and easily plugs into existing distributed storage systems. ResolutionMD’s federated approach is an important differentiator from other solutions as highly sensitive data is never moved to a device and no additional data storage locations are created. ResolutionMD is currently installed in leading healthcare institutions around the world via a network of more than forty-five world class healthcare partners. For more information on ResolutionMD, go to www.calgaryscientific.com/resolutionmd.

About Calgary Scientific Inc.

Calgary Scientific is the global leader in web and mobile diagnostic medical imaging and cloud enabling solutions. For more information on Calgary Scientific, go to www.calgaryscientific.com.

© 2014 Calgary Scientific Inc., ResolutionMD, PureWeb and the Calgary Scientific logo are trademarks and/or registered trademarks of Calgary Scientific Inc. or its subsidiaries. Any third-party company names and products are for identification purposes only.

CONTACT

Calgary Scientific Inc.
Jennifer Sobotka, (+1) 403-767-7941
Director
of Marketing
Jennifer.Sobotka@calgaryscientific.com
or
Calgary
Scientific Inc.
Byron Osing, (+1) 403-767-7959
CEO and Chair
Byron.Osing@calgaryscientific.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗